Position summary Under the authority of the Early Stage Clinical Trial (ESCT) Initiative’s Steering committee and in collaboration with the President and Chief Executive Officer of CQDM, the selected candidate will be responsible for the Initiative start-up, the elaboration and the implementation of the action plan for the Early Stage Clinical Trial (ESCT) Initiative. About…
DIRECTOR OF COMMUNICATIONS AND PUBLIC RELATIONS Position Summary Reporting to the President and Chief Executive Officer of CQDM, the Director will play a lead role in 3 key aspects of the organization: communications, public relations and government affairs. Furthermore, the selected candidate will be involved in other initiatives/consortium associated with CQDM or its partners. About…
Montreal, November 24, 2016 – Richard Fajzel, Chairman of the Board of Directors and Diane Gosselin, President and CEO of CQDM are very pleased to announce the appointment of two new members on the Board: Patrick Wier, Senior Vice President, In vitro/In vivo Translation Platform at GSK and Jorge Puente, co-founder and managing partner of Pleasanton Pharma Ventures.…
Montreal, September 19, 2016 – The Chairman of CQDM’s Board of Directors, Richard Fajzel and Diane Gosselin, President and CEO of CQDM are pleased to announce the appointment of Ali Tehrani, Co-founder, President and CEO of Zymeworks, and audacious entrepreneur, as new member of the Board. Ali Tehrani is well known in Canada and internationally for…
Montréal, August 25, 2016. – CQDM salutes the extraordinary breakthrough in the fight against cancer uncovered by Professor Sylvain Martel and his team at Polytechnique Montréal. The researchers developed a first-in-kind medical intervention platform that guides nanobots across the vasculature of a living organism to deliver therapeutics at the core of tumors. CQDM granted $1.9…
San Francisco, June 7, 2016. – Partners since 2012, CQDM and Ontario Centres of Excellence (OCE) are pleased to announce the funding of six new game-changing research projects to accelerate drug discovery under the Quebec-Ontario Life Sciences Corridor, for a total of $1.8M invested. The projects are part of the Explore program and were announced…
Protein trafficking and misfolding under scrutiny Berlin, May 26, 2016. – CQDM is proud to announce the funding of the first project under the Canada/Germany Program with partner the German Federal Ministry for Economic Affairs and Energy (BMWi), through its ZIM Program, for a total of $1M. This announce has been made today at the…
A World First at the Montreal Heart InstituteA discovery in precision medicine that will change patients’ lives Montreal, April 5, 2016 – During the annual meeting of the American College of Cardiology (ACC) in Chicago, a researcher from the Montreal Heart Institute (MHI) presented the results of a phase II clinical study demonstrating the safety of…
CQDM is pleased to announce the publication of its 2015 Activity Report. We are proud of our achievements as 2015 has been a year of partnerships. We furthered our collaborations in Europe by forging two key partnerships with Belgium and Germany, while consolidating our activities across Canada. Just this year, we launched 15 new projects involving…
Montreal, February 18, 2016 – The members of CQDM’s Board of Directors are pleased to announce the appointment of Richard Fajzel as new Chairman of the Board. Richard replaces Leon Gosselin who held the position of Chairman since its founding in 2008 and is leaving for a well-deserved retirement. CQDM and the members of the Board…